Key result
DAPT reduces ischemic events after ACS and PCI but consistently increases major bleeding.
Personalized assessment of ischemic versus bleeding risks is essential for tailoring the optimal duration and intensity of anti-platelet therapy in ischemic heart disease.
Answers are grounded in this paper and cite their sources.
Requires individualized ischemic-bleeding risk assessment for DAPT duration in ACS/PCI; leaves open optimal personalization strategies.
Acetylsalicylic acid remains the basis of anti-platelet therapy for stable ischemic heart disease (IHD), including conditino after coronary artery bypass grafting. Double anti-platelet therapy (APT) consisting of acetylsalicylic acid and a P2Y12 receptor inhibitor (clopidogrel, prasugrel, ticagrelor) reduces the risk of recurrence of major ischemic complications in patients with acute coronary syndromes (ACS) and/or those who underwent percutaneous coronary intervention (PCI), but inevitably increases the risk of major bleeding compared with anti-platelet monotherapy. The principle of personified treatment is implemented on the basis of an assessment of the patient’s clinical status (stable ischemic heart disease or ACS), the ratio of the ischemic and bleeding risks, strategies of management. The review presents the evidence-base to support anti-platelet therapy of stable IHD and ACS in conservative treatment and myocardial revascularization, which forms the basis of the current clinical guidelines. According to the current views the optimal duration of APT after ACS and PCI can vary from 1 to 48 months and continues to be studied in randomized trials. Most recently, the principle of de-escalation of anti-platelet therapy after ACS and PCI has been developed, taking into account the actively discussed findings of clinical projects published in the second half of 2017.
No takes yet. Share an insight, caveat, or question.
S. G. Kanorsky (2018) conducted a review in Ischemic heart disease. Anti-platelet therapy was evaluated. Dual anti-platelet therapy reduces the risk of recurrent major ischemic complications in acute coronary syndrome and percutaneous coronary intervention patients but inevitably increases the risk of major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: